Home > Dermatology > EADV 2022 > Novel JAK inhibitor deuruxolitinib effective in alopecia areata

Novel JAK inhibitor deuruxolitinib effective in alopecia areata

Presented By
Prof. Brett King, Yale University School of Medicine, CT, USA
Conference
EADV 2022
Trial
Phase 3, THRIVE-AA1
The investigative JAK inhibitor deuruxolitinib showed to be highly effective in severe alopecia areata (AA) in the phase 3 THRIVE-AA1 trial. The positive results were mirrored in a high percentage of satisfied or very satisfied patients. The JAK inhibitor also led to the re-growth of eyebrows. THRIVE-AA1 (NCT04518995) is a multinational, phase 3 trial in adult patients with severe AA, aiming to assess the efficacy and safety of the novel JAK inhibitor deuruxolitinib with a study duration of up to 32 weeks [1]. Participants were treated with either 8 mg or 12 mg deuruxolitinib twice daily or placebo and had at least 50% scalp hair loss as measured by Severity of Alopecia Tool (SALT). The primary efficacy endpoint was the percentage of participants achieving a SALT score of ≤20 at week 24. “We also looked at patient satisfaction,” Prof. Brett King (Yale Unive...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on